1. A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide. (December 2016) Authors: Denmeade, S.; Antonarakis, E.; Paller, C.; Wang, H.; Benjamin, T.; Drake, C.; Carducci, M.; Eisenberger, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗